Description
Minoxytop (Minoxidil) 5% solution
Minoxytop 5% solution is a topical minoxidil product for scalp use. Minoxidil is used for androgenetic alopecia, a common pattern hair-loss condition. The verified product description indicates a 60 mL bottle, but the medicine content is best identified by the active ingredient: minoxidil.
Active Ingredient and Medicine Class
Active ingredient: minoxidil 5% w/v.
Medicine class: topical hair-regrowth treatment; pharmacologically, minoxidil is an arteriolar vasodilator. Regulatory labeling and review articles describe it as a topical treatment for androgenetic alopecia in men and women.
Established Medical Uses
Topical minoxidil is an established treatment for androgenetic alopecia, including pattern hair loss on the scalp. FDA/DailyMed labeling for 5% minoxidil solution identifies hair regrowth use on the scalp, and peer-reviewed reviews describe topical minoxidil as an FDA-approved option for androgenetic alopecia in both men and women.
How It Works
The exact mechanism is not fully established. Published reviews describe several proposed actions, including effects on blood vessel tone, anti-inflammatory activity, stimulation of Wnt/β-catenin signalling, and prolongation of the hair-growth phase while shortening the resting phase.
Important Safety Information
Minoxidil 5% topical solution is for external scalp use and should not be used on broken, irritated, inflamed, or infected skin. DailyMed/FDA labeling states it is not intended for frontal baldness or a receding hairline, and it should not be used in children. Important precautions include avoiding eye contact and not using other scalp medicines unless advised by a clinician. Minoxidil can interact clinically with other topical products on the scalp, and excess use does not improve results.
Possible Side Effects
Reported adverse effects include scalp irritation, redness, itching, dryness, and unwanted changes in hair color or texture. More serious reactions are uncommon but can include widespread allergic or irritation reactions, dizziness, chest symptoms, swelling, or other signs of systemic absorption.
Scientific Evidence
A systematic review and meta-analysis found topical minoxidil to be more effective than placebo for promoting hair growth in androgenetic alopecia. A later review also reported that 5% topical formulations increase hair counts, though response varies between individuals.
Medical Information Notice
This educational summary is based on sources available at the time of review and does not replace the official patient leaflet, product label, or assessment by a qualified healthcare professional.
Medical Sources
- DailyMed (U.S. National Library of Medicine) — Minoxidil topical solution, 5% — Drug Label Information
- Gupta AK, Charrette A. — Topical Minoxidil: Systematic Review and Meta-Analysis of Its Efficacy in Androgenetic Alopecia — Skinmed, 2015
